Trial Profile
A Dose Blocked-randomized, Double-blind, Active and Placebo Controlled, Single and Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2018
Price :
$35
*
At a glance
- Drugs LC 231306 (Primary) ; Ticagrelor
- Indications Acute coronary syndromes; Arterial thrombosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors LG Life Sciences
- 06 Aug 2013 Status changed from recruiting to completed, as replyed by the investigator of the trial (dongyeopshin@lgchem.com). Comment: "The study was completed already and I found that the status update was not applied properly at that time. Last Patient Out date of MAD study is 6 Aug 2013 ".
- 09 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Apr 2012 Actual initiation date 1 Mar 2012 added as reported by ClinicalTrials.gov.